Anti Asthma Drug

Asthma Protocol Version 1.4

A Randomized, Double-Blind, Controlled Study of A Herbomineral

Preparation of Divya Pharmacy in Adult Patients of mild to moderate
Bronchial Asthma

Avnish K. Upadhyay

Department of Clinical Research & Drug Development

Divya Yog Mandir Trust,
Patanjali Yog Peeth , Haridwar

RCT Asthma 1
 Anti Asthma Drug

TABLE OF CONTENTS

1. INTRODUCTION

1.1. Background
1.2. Hypothesis

2. STUDY OBJECTIVES

3. STUDY DESIGN

3.1. Study population

3.1.1. Inclusion Criteria
3.1.2. Exclusion Criteria
3.2. Study Observations
3.2.1. Screening Visit
3.2.2. Visit One
3.2.3. Subsequent three monthly visits

4. PATIENT WITHDRAWAL

5. TREATMENT ADMINISTERED

5.1. Randomization of Subjects

5.2. Dosage and Administration
5.2.1. Control Group
5.2.2. Swasnashini (An Ayurvedic Preparation by Divya Pharmacy)

6. EFFICACY VARIABLES

6.1. Primary Endpoints

6.2. Secondary Endpoints

7. DATA ANALYSIS METHODS

7.1. Sample Size

7.2. Randomization
7.3. General Consideration
7.4. Statistical Methods

8. DATA COLLECTION

8.1 Demographics

RCT Asthma 2
 Anti Asthma Drug

9. CLINICAL AND LAB PROCEDURES

9.1. Clinical Laboratory Assesments

10. REFERENCES

11. TABLE. TIME AND EVENT SCHEDULE

RCT Asthma 3
 Anti Asthma Drug

1. INTRODUCTION

1.1. Background

Asthma is a chronic illness involving the respiratory system in which the airway
occasionally constricts, becomes inflamed, and is lined with excessive amounts of mucus,
often in response to one or more triggers. These episodes may be triggered by such things
as exposure to an environmental stimulant (or allergen), cold air, warm air, moist air,
exercise or exertion, or emotional stress. In children, the most common triggers are viral
illnesses such as those that cause the common cold.(1) This airway narrowing causes
symptoms such as wheezing, shortness of breath, chest tightness, and coughing. The
airway constriction responds to bronchodilators. Between episodes, most patients feel
well but can have mild symptoms and they may remain short of breath after exercise for
longer periods of time than the unaffected individual. The symptoms of asthma, which
can range from mild to life threatening, can usually be controlled with a combination of
drugs and environmental changes.

Public attention in the developed world has recently focused on asthma because of its
rapidly increasing prevalence, affecting up to one in four urban children.(2)

The word 'asthma' is derived from the Greek aazein, meaning "sharp breath." The word
first appears in Homer's Iliad;(3) Hippocrates was the first to use it in reference to the
medical condition, in 450 BC. Hippocrates thought that the spasms associated with
asthma were more likely to occur in tailors, anglers, and metalworkers. Six centuries
later, Galen wrote much about asthma, noting that it was caused by partial or complete
bronchial obstruction. In 1190 AD, Moses Maimonides, an influential medieval rabbi,
philosopher, and physician, wrote a treatise on asthma, describing its prevention,
diagnosis, and treatment/(4) In the 17th century, Bernardino Ramazzini noted a
connection between asthma and organic dust. The use of bronchodilators started in 1901,
but it was not until the 1960s that the inflammatory component of asthma was
recognized, and anti-inflammatory medications were added to the regimens.

In some individuals asthma is characterized by chronic respiratory impairment. In others

it is an intermittent illness marked by episodic symptoms that may result from a number
of triggering events, including upper respiratory infection, stress, airborne allergens, air
pollutants (such as smoke or traffic fumes), or exercise. Some or all of the following
symptoms may be present in those with asthma: dyspnea, wheezing, stridor, coughing, an
inability for physical exertion. Some asthmatics that have severe shortness of breath and
tightening of the lungs never wheeze or have stridor and their symptoms may be confused
with a COPD-type disease.

An acute exacerbation of asthma is referred to as an asthma attack. The clinical

hallmarks of an attack are shortness of breath (dyspnea) and either wheezing or stridor.(6)
Although the former is "often regarded as the sine qua non of asthma,(5) some patients

RCT Asthma 4
 Anti Asthma Drug

present primarily with coughing, and in the late stages of an attack, air motion may be so
impaired that no wheezing may be heard. When present the cough may sometimes
produce clear sputum. The onset may be sudden, with a sense of constriction in the chest,
breathing becomes difficult, and wheezing occurs (primarily upon expiration, but can be
in both respiratory phases). An asthma attack may spread the mold to others through the
air.

Signs of an asthmatic episode include wheezing, rapid breathing (tachypnea), prolonged

expiration, a rapid heart rate (tachycardia), rhonchous lung sounds (audible through a
stethoscope), and over-inflation of the chest. During a serious asthma attack, the
accessory muscles of respiration (sternocleidomastoid and scalene muscles of the neck)
may be used, shown as in-drawing of tissues between the ribs and above the sternum and
clavicles, and the presence of a paradoxical pulse (a pulse that is weaker during
inhalation and stronger during exhalation).

During very severe attacks, an asthma sufferer can turn blue from lack of oxygen, and
can experience chest pain or even loss of consciousness. Just before loss of
consciousness, there is a chance that the patient will feel numbness in the limbs and
palms may start to sweat. Feet may become icy cold. Severe asthma attacks, which may
not be responsive to standard treatments (status asthmaticus), are life-threatening and
may lead to respiratory arrest and death. Despite the severity of symptoms during an
asthmatic episode, between attacks an asthmatic may show few signs of the disease.(6)

Asthma is defined simply as reversible airway obstruction. Reversibility occurs either

spontaneously or with treatment. The basic measurement is peak flow rates and the
following diagnostic criteria are used by the British Thoracic Society.(7)

≥20% difference on at least three days in a week for at least two weeks;

≥20% decrease in peak flow following exposure to a trigger (e.g., exercise).

In many cases, a physician can diagnose asthma on the basis of typical findings in a
patient's clinical history and examination. Asthma is strongly suspected if a patient
suffers from eczema or other allergic conditions—suggesting a general atopic
constitution—or has a family history of asthma. While measurement of airway function is
possible for adults, most new cases are diagnosed in children who are unable to perform
such tests. Diagnosis in children is based on a careful compilation and analysis of the
patient's medical history and subsequent improvement with an inhaled bronchodilator
medication. In adults, diagnosis can be made with a peak flow meter (which tests airway
restriction), looking at both the diurnal variation and any reversibility following inhaled
bronchodilator medication.

Asthma is categorized by the United States National Heart, Lung and Blood Institute as
falling into one of four categories: mild intermittent, mild persistent, moderate persistent
and severe persistent. The diagnosis of "severe persistent asthma" occurs when symptoms
are continual with frequent exacerbations and frequent nighttime symptoms, result in

RCT Asthma 5
 Anti Asthma Drug

limited physical activity and when lung function as measured by PEV or FEV 1 tests is
less than 60% predicted with PEF variability greater than 30%.

During an asthma episode, inflamed airways react to environmental triggers such as

smoke, dust, or pollen. The airways narrow and produce excess mucus, making it
difficult to breathe. In essence, asthma is the result of an immune response in the
bronchial airways.(8)

Many asthmatics, like those who suffer from other chronic disorders, use alternative
treatments; surveys show that roughly 50% of asthma patients use some form of
unconventional therapy.(9,10) There are little data to support the effectiveness of most of
these therapies. A Cochrane systematic review of acupuncture for asthma found no
evidence of efficacy.(11) A similar review of air ionisers found no evidence that they
improve asthma symptoms or benefit lung function; this applied equally to positive and
negative ion generators.(12) A study of "manual therapies" for asthma, including
osteopathic, chiropractic, physiotherapeutic and respiratory therapeutic manoeuvers,
found there is insufficient evidence to support or refute their use in treating asthma;(13)
these manoeuvers include various osteopathic and chiropractic techniques to "increase
movement in the rib cage and the spine to try and improve the working of the lungs and
circulation"; chest tapping, shaking, vibration, and the use of "postures to help shift and
cough up phlegm." On the other hand, one meta-analysis found that homeopathy has a
potentially mild benefit in reducing symptom intensity.(14) however, the number of
patients involved in the analysis was small, and subsequent studies have not supported
this finding.(15) Several small trials have suggested some benefit from various yoga
practices, ranging from integrated yoga programs(16) —"yogasanas, Pranayama,
meditation, and kriyas"—to sahaja yoga,(17) a form of meditation.

In Ayurveda, Asthma is known as 'Swas Roga'. Samprapti (Pathogenesis) of the swas

roga according to Ayurveda is "The vitiated 'Pranvayu' combines with deranged 'Kapha
dosha' in the lungs causing obstruction in the 'Pranavaha srotasa'(Respiratory passage).
This results in gasping and laboured breathing. This condition is known as 'Swas Roga'"
Five types of 'Swas Roga' are described in Ayurvedic texts
1]Maha-shwas
2]Urdhva-shwas
3]Chinna-shwas
4]Tamak-shwas
5]Kshudra-shwas
Among these five types first three are not curable. 'Tamak-shwas is 'yapya'(Controllable)
and is difficult to cure. The last one is curable. More than 75% of the cases belong to last
two catagories.(18)

Ayurvedic medicines are very safe and cure the problem to a great extent. Scholars of
various disciplines are working on the problem and various modern means and measures
have been discovered. Even then the effective drug without any reaction couldn’t be
established. Ayurveda is the reach source of the therapeutic measures that can control the

RCT Asthma 6
 Anti Asthma Drug

disease. Out of such therapeutic measures a poly-herbal compound is selected for the
benefit of the increasing number of asthma patients.

A Herbomineral combination of Divya Pharmacy found very much effective in Asthama

patients in General Practice containing Glycyrhiza glabra, Justicia gendarussa, Solanum
surattenes, Adhatoda vasica, Ocimum sanctum, Cinnamomum zeylanicum, Zingiber
officinale, Abhrak Bhasma, Swarn Basant Malti, Sanjivani Vati etc.To treat this
widespread disease there is a high prevalence of usage of herbal medicine. The use of
plants is as old as humankind and it has been steadily increasing over the past 10 years.
Plant-based remedies are now one of the most popular complementary treatments. Herbal
supplements are receiving increasing exposure through media, including the Internet, in
lay journals and more recently in the scientific press. Interest in herbal medicine has been
facilitated by multiple factors, including the perception that pharmaceutical medications
are expensive, overprescribed and may often be dangerous. Alternatively, herbal
medicine is often perceived as being "natural" and therefore is considered safe. (19)

The antitussive activity of Adhatoda vasica (AV) extract was evaluated in anaesthetized
guinea pigs and rabbits and in unanaesthetized guinea pigs. AV was shown to have a
good antitussive activity. Intravenously, it was 1/20–1/40 as active as codeine on
mechanically and electrically induced coughing in rabbits and guinea-pigs. After oral
administration to the guinea-pig the antitussive activity of AV was similar to codeine
against coughing induced by irritant aerosols. Adhatoda vasica (L.) Nees is a well-known
plant drug in Ayurvedic and Unani medicine. It has been used for the treatment of various
diseases and disorders, particularly for the respiratory tract ailments. During the last 20
years, several scientific reports on oxytocic and abortifacient effects of vasicine and
alkaloid derived from the plant have appeared. This leads to questions concerning the
safety of A. vasica as a herbal medicine. In this article, the major data on traditional uses
as well as ethnopharmacological and toxicological studies, both published and
unpublished, are reviewed and commented upon. The data have been evaluated from the
point of view of correctness, reliability, relevance and importance for the overall
evaluation of the safety of A. vasica. (20, 21)

Several plants are used in traditional medicine for the treatment of bronchial asthma. We
are trying to identify the active compound(s) and their mode of action. For the isolation
and identification of the active principles, different chromatographic methods, HPLC,
MPLC, elementary analysis, UV, mass, 1H- and 13C-NMR spectroscopy are used.
Whole plant extracts, fractionated extracts and pure compounds are tested in the
following pharmacological systems: cyclooxygenase and lipoxygenase pathway of
arachidonic acid metabolism, bronchial obstruction of guinea pigs after inhalation of
allergens, platelet-activating factor (PAF), histamine or acetylcholine, PAF-induced
bronchial hyperreactivity of guinea pigs, histamine release, chemoluminescence and
chemotaxis of human polymorphonuclear leukocytes as well as thromboxane
biosynthesis of human platelets. As active compounds in onion extracts, thiosulfinates
and cepaenes could be identified. They exert a wide spectrum of pharmacologic
activities, both in vitro and in vivo. Tetragalloyl quinic acid from Galphimia glauca,
suppressed allergen- and PAF-induced bronchial obstruction, PAF-induced bronchial

RCT Asthma 7
 Anti Asthma Drug

hyperreactivity (5 mg/kg orally) in vivo and thromboxane biosynthesis in vitro. Hitherto

unknown alkaloids from Adhatoda vasica showed pronounced protection against
allergen-induced bronchial obstruction in guinea pigs (10 mg/ml aerosol). Androsin from
Picrorhiza kurroa prevented allergen- and PAF-induced bronchial obstruction (10 mg/kg
orally; 0.5 mg inhalative). Histamine release in vitro was inhibited by other compounds
of the plant extract yet to be identified. Pharmacological effects of plant extracts and pure
compounds in man are under investigation. (22)

To identify the inhibitor of prednisolone metabolism contained in Saiboku-To, we

conducted in-vitro experiments of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD),
using rat liver homogenate and cortisol as a typical substrate. We studied the effects of
ten herbal constituents on 11 beta-HSD. Five herbal extracts showed inhibitory activity
with Glycyrrhiza glabra > Perillae frutescens > Zizyphus vulgaris > Magnolia officinalis
> Scutellaria baicalensis. This suggests that unknown 11 beta-HSD inhibitors are
contained in four herbs other than G. glabra which contains a known inhibitor,
glycyrrhizin (and glycyrrhetinic acid). Seven chemical constituents which have been
identified as the major urinary products of Saiboku-To in healthy and asthmatic subjects
were studied; magnolol derived from M. officinalis showed the most potent inhibition of
the enzyme (IC50, 1.8 x 10(-4) M). Although this activity was less than that of
glycyrrhizin, the inhibition mechanism (non-competitive) was different from a known
competitive mechanism. These results suggest that magnolol might contribute to the
inhibitory effects of Saiboku-To on prednisolone metabolism through inhibition of 11
beta-HSD. (23)

Ocimum sanctum (OS) has been mentioned in Indian system of traditional medicine to be
of value in the treatment of diabetes mellitus. We have previously shown that OS shows a
dose-dependent hypoglycemic effect and prevented rise in plasma glucose in normal rats.
It also showed significant antihyperglycemic effect in STZ-induced diabetes. The present
study was undertaken to assess the effect of OS on three important enzymes of
carbohydrate metabolism [glucokinase (GK) (EC 2.7.1.2), hexokinase (HK) (EC 2.7.1.1)
and phosphofructokinase (PFK) (EC 2.7.1.11)] along with glycogen content of insulin-
dependent (skeletal muscle and liver) and insulin-independent tissues (kidneys and brain)
in STZ (65 mg/kg) induced model of diabetes for 30 days. Administration of OS extract
200 mg/kg for 30 days led to decrease in plasma glucose levels by approximately 9.06
and 26.4% on 15th and 30th day of the experiment. Liver and two-kidney weight
expressed as percentage of body weight significantly increased in diabetics (P<0.0005)
versus normal controls. OS significantly decreased renal (P<0.0005) but not liver weight.
Renal glycogen content increased by over 10 folds while hepatic and skeletal muscle
glycogen content decreased by 75 and 68% in diabetic controls versus controls. OS did
not affect glycogen content in any tissue. Activity of HK, GK and PFK in diabetic
controls was 35, 50 and 60% of the controls and OS partially corrected this alteration.(24)

In another study the ethanolic extract of the leaves exhibited a hypoglycemic effect in rats
and an antispasmodic effect in isolated guinea pig ileum. Tulsi extract was administered
to 20 patients with shortness of breath secondary to tropical eosinophia in an oral dosage

RCT Asthma 8
 Anti Asthma Drug

of 500 mg TID and an improvement in breathing was noted. The aqueous extract showed
a hypotensive effect on anesthetised dogs and cats and negative inotropic and
chronotropic activity (reduces the force and rate, respectively) on rabbit's heart.
Antibacterial activity has been shown against Staphlococcus aureus and Mycoplasma
tuberculosis in vitro as well as against several other species of pathogens including fungi.
The plant has had general adaptogenic effects in mice and rats and has been shown to
protect against stress-induced ulcers. It has also shown to be protective against histamine-
induced bronchospasm in animals. The leaf infusion or fresh leaf juice is commonly used
in cough, mild upper respiratory infections, bronchospasm, stress-related skin disorders
and indigestion. It is combined with ginger and maricha (black pepper) in bronchial
asthma. It is given with honey in bronchitis and cough. The leaf juice is taken internally
and also applied directly on cutaneous lesions in ringworm. The essential oil has been
used in ear infections. The seeds are considered a general nutritious tonic.(25,26,27)

Spices are the most attractive ingredients to confer an authentic taste to food. As they are
derived from plants, they harbour allergenic potency and can induce symptoms ranging
from mild local to severe systemic reactions. Due to the content of pharmacologically
active substances of spices, the diagnosis of allergy and the differentiation from
intolerance reactions may be difficult. Association with inhalative allergies via IgE cross-
reactivity, but also direct gastrointestinal sensitization plays a role. This article is a
botanical and allergological overview of the most important spices and molecules
responsible for eliciting IgE-mediated reactions or cross-reactions. As no curative
treatments are known at present, strict avoidance is recommended and, therefore, accurate
labelling of pre-packed food is necessary. (28)

In a placebo-controlled study the effect of ginger and fenugreek was examined on blood
lipids, blood sugar, platelet aggregation, fibrinogen and fibrinolytic activity. The subjects
included in this study were healthy individuals, patients with coronary artery disease
(CAD), and patients with non-insulin-dependent diabetes mellitus (NIDDM) who either
had CAD or were without CAD. In patients with CAD powdered ginger administered in a
dose of 4 g daily for 3 months did not affect ADP- and epinephrine-induced platelet
aggregation. Also, no change in the fibrinolytic activity and fibrinogen level was
observed. However, a single dose of 10 g powdered ginger administered to CAD patients
produced a significant reduction in platelet aggregation induced by the two agonists.
Ginger did not affect the blood lipids and blood sugar. Fenugreek given in a dose of 2.5 g
twice daily for 3 months to healthy individuals did not affect the blood lipids and blood
sugar (fasting and post prandial). However, administered in the same daily dose for the
same duration to CAD patients also with NIDDM, fenugreek decreased significantly the
blood lipids (total cholesterol and triglycerides) without affecting the HDL-c. When
administered in the same daily dose to NIDDM (non-CAD) patients (mild cases),
fenugreek reduced significantly the blood sugar (fasting and post prandial). In severe
NIDDM cases, blood sugar (both fasting and post prandial) was only slightly reduced.
The changes were not significant. Fenugreek administration did not affect platelet
aggregation, fibrinolytic activity and fibrinogen.(29)

RCT Asthma 9
 Anti Asthma Drug

DCBT4567-Astha-15 (Plant based formulation for Bronchial Asthma), salbutamol and

sal- butamol + theophylline patients showed statistically significant improvement in FEV
1 , while placebo patients did not show any improvement. Fifty percent of DCBT4567-
Astha-15, 48% of salbutamol, 58% of salbutamol + theophylline and 26% of placebo
patients showed the desired 15% improvement in FEV 1 . Improved mean FEV 1 values
at the end of the trial indicated that the salbutamol - theophylline combination was
superior followed by salbutamol and DCBT4567-Astha-15. Clinical symptoms like
dyspnoea, wheezing, cough, expectoration,
disability, and sleep disturbances were significantly reduced in DCBT4567-Astha-15
patients compared to patients of the other three arms.(30)

Herbs and spices have been used for generations by humans as food and to treat ailments.
Scientific evidence is accumulating that many of these herbs and spices do have
medicinal properties that alleviate symptoms or prevent disease. A growing body of
research has demonstrated that the commonly used herbs and spices such as garlic, black
cumin, cloves, cinnamon, thyme, allspices, bay leaves, mustard, and rosemary, possess
antimicrobial properties that, in some cases, can be used therapeutically. Other spices,
such as saffron, a food colorant; turmeric, a yellow colored spice; tea, either green or
black, and flaxseed do contain potent phytochemicals, including carotenoids, curcumins,
catechins, lignan respectively, which provide significant protection against cancer. This
review discusses recent data on the antimicrobial and chemopreventive activities of some
herbs and spices and their ingredients. (31)

Datura contains tropane alkaloids that are sometimes used as a hallucinogen. The active
ingredients are atropine, hyoscyamine and scopolamine which are classified as deliriants,
or anticholinergics. (32)

Cassia fistula is a deciduous tree with exfoliating bark. The pulp contains sennosides A
and B, Rhein and its glucoside, barbaloin, aloin, formic acid, butyric acid, their ethyl
esters and oxalic acid. It is a safe purgative given even to pregnant women. The pulp is
also given for biliousness and in disorders of the liver. It is applied in gout and
rheumatism. It is utilized in blood-poisoning, anthrax and dysentery, also given in leprosy
and diabetes and for the removal of abdominal obstructions. It is used in the treatment of
varicose veins. It helps in shrinking engorged veins and has a powerful anti-inflammatory
effect. (33)

Abhrak (Bhasma Biotite) Abhrak is considered to be a tonic. In combination with iron

preparation, it is used in chronic diseases. Prepared from black mica with the juice of
various indegenous drugs. Tonic, Alterative, Haematinic and Aphrodisiac. Gives strength
to the body.(34) Shringa Bhasma is expectorant and diaphoretic, indicated in bronchitis,
pneumonia, tuberculosis, cough and cold widely used by ancient traditional practitioners.
(34)

RCT Asthma 10
 Anti Asthma Drug

In so many clinical studies herbs and herbomineral preparations of Ayurveda found

useful in different type of Respiratory disorders like Bronchial Asthma. (35-60)

1.2. Hypothesis

Allergic respiratory disorders, in particular asthma are increasing in prevalence, which is

a global phenomenon. Even though genetic predisposition is one of the factors in children
for the increased prevalence - urbanisation, air pollution and environmental tobacco
smoke contribute more significantly. Our hospital based study on 20,000 children under
the age of 18 years from 1979,1984,1989,1994 and 1999 in the city of Bangalore showed
a prevalence of 9%,10.5%,18.5%, 24.5% and 29.5% respectively. The increased
prevalence correlated well with demographic changes of the city. Further to the hospital
study, a school survey in 12 schools on 6550 children in the age group of 6 to 15 years
was undertaken for prevalence of asthma and children were categorized into three groups
depending upon the geographical situation of the school in relation to vehicular traffic
and the socioeconomic group of children. Group I-Children from schools of heavy traffic
area showed prevalence of 19.34%, Group II-Children from heavy traffic region and low
socioeconomic population had 31.14% and Group III-Children from low traffic area
school had 11.15% respectively. (P: I & II; II & III <0.001). A continuation of study in
rural areas showed 5.7% in children of 6-15 years. The persistent asthma also showed an
increase from 20% to 27.5% and persistent severe asthma 4% to 6.5% between 1994-99.
Various epidemiological spectra of asthma in children are discussed here. (61)

The concept delineated in the project will be elucidated by scientific insight and
investigation. Thus a number of basic concepts may emerge which are academically
significant. The broad and in depth study spectrum will raise many problems as
well as their solution. Ultimately the results will come out as substantial scientific
contributions. It is also envisaged that this project will help the developing countries like
India to treat the Asthma at very low cost.

2. STUDY OBJECTIVES

The assessment of Effect of Herbomineral Preparation in patients of Bronchial Asthma.

The result of this study will decide long term study on different type of Asthmatic
patients.

3. STUDY DESIGN

3.1. Study population

3.1.1. Inclusion Criteria

1. Male or female 18-50 years of age (inclusive).

2. Diagnosis of asthma for at least 6 months.
3. Morning FEV1 of 40-80% normal.
4. Demonstrated reversible airflow restriction.

RCT Asthma 11
 Anti Asthma Drug

5. Non-smokers.
6. On moderate doses of ICS with inadequate asthma control.
7. Signed ICF

3.1.2. Exclusion Criteria

1. Diagnosis of COPD.
2. Uncontrolled systemic illness.
3. Hypersensitivity to any component of Investigational Drug.
4. Any patient with an unscheduled visit to an ER or hospital for asthma
exacerbation within past 3 months.
5. History of hepatitis or active liver disease.
6. ALT greater than 3xULN.
7. History of HIV infection
8. Recent history of drug or alcohol abuse.
9. Oral corticosteroids within one month, cromolyn sodium or nedocromil within 14
days, theophylline, LABA, ZYFLO, or leukotriene modifiers, warfarin or
propranolol, inhaled anti-cholinergics, or combination LABA/ICS.
10. Omalizumab within 3 months.
11. Pregnant female.
12. Participation with 30 days in investigational study.

3.2. Study Observations

3.2.1. Screening Visit

A maximum of 7-8 days elapse between screening and the start of treatment. Patients will
be randomized and assigned an identification number during the screening visit.

The following procedure will be performed:

1. Patient must sign informed consent form.

2. Physical examination.

3. Collection of blood for cytochemistry, biochemistry and haematology analysis.

4. Record of Vital signs

The following information will be recorded:

1. Demographics including – Date of birth, Gender and race.

2. Height, Weight

3. Primary disease.

RCT Asthma 12
 Anti Asthma Drug

3.2.2. Visit One

Visit one will take place around 30 days after treatment starts.

The following procedure will be performed:

1. Physical examination.

2. Collection of blood for cytochemistry, biochemistry and haematology analysis.

3. Record of Vital signs

The following information will be recorded:

1. Date treatment started

2. Weight

3.2.3. Subsequent three monthly visits

Treatment period continues for twelve months. Patients will be with drawn from the
study if they have life threatening problem.

The following procedure will be performed:

1. Physical examination.

2. Collection of blood for cytochemistry, biochemistry and haematology analysis.

3. Record of Vital signs

The following information will be recorded:

1. Treatment regime

2. Weight

4. PATIENT WITHDRAWAL

Patients are withdrawn from the study for any of the following reasons:

1. Completion of study

2. Patient preference

RCT Asthma 13
 Anti Asthma Drug

3. Death

4. Physician discretion

5. TREATMENT ADMINISTERED

5.1. Randomization of Subjects

Patients will be randomized 1:1

1 (Control group) : Standard Life Style

1 Treatment Group (Herbomineral Preparation By Divya Pharmacy)
fashion and followed for one year.

5.2. Dosage and Administration

5.2.1. Control Group

The Control group will not receive any type of treatment. This group will receive
Standard Life Style (SLS)

5.2.1. Treatment Group (Herbomineral Preparation by Divya Pharmacy)

The ingredients is as followes:

Each 750 mg Capsule or Tablet contains
Name Botanical/English Name/Reference Qty. (mg.)
Extract of
Madhuyashti Glycyrhiza glabra 220
Kateli Choti Solanum surattenes 110
Kala Vasa Justicia gendarussa 110
Safed Vasa Adhatoda vasica 110
Vanafsa Panchang Viola odorata 110
Desi Tulsi Panchang Ocimum sanctum 110
Choti Peepal Piper peepuloids 110
Dal Chini Cinnamomum zeylanicum 220
Lavang Syzygium aromaticum 220
Saunth Zingiber officinale 110
Dhatura Panchang Datura stramonium 110
Tej Patra Cinnamomum tamala 110
Bharangi Clerodendrum serratum 110
Lisoda Cordia dichotoma 110

RCT Asthma 14
 Anti Asthma Drug

Amaltas Cassia fistula 110

Kakrasringi Pistacia integrrima 110
Rudanti Phal Capparis moon 110
Akarkara mool Anacyclus pyrethrum 110
Powders of
Abhrak Bhasma AFI Page 9 40
Praval Pishti RT Page 177 40
Trikatu Churna Bh.R. 200
Srnga Bhasma ****** 85
Swarn Basant Malti ASS Page 407 17
Godanti Bhasm AFI Page 185 40
Muktasukti Bhasm RT Page 296 40
Laxmi Vilas Ras AFI Page 214 165
Sanjivani Vati RTS Page 189 85

Two tablets will be given to subjects in treatment group before meal at 7.00AM Morning
and 6.00PM evening with simple water or should be chewed. The subjects in both group
will be on control diet.

6. EFFICACY VARIABLES

6.1. Primary Endpoints

Pulmonary function measures [Time Frame: 3 and 6 months]

(A) Breath holding time – measured by stop watch.

(B) Vital capacity-measured by an instrument called Spirometer.

(C) Peak expiratory flow rate measured with help of Peak flow meter.

6.2. Secondary Endpoints

1. Asthma exacerbations, ACQ, AQLQ, safety [Time Frame: 3 and 6 months]

2. BLOOD : T.L.C. ; D.L.C. ; Hb% ; E.S.R. ; P.P.B.S., URINE : RE / ME , CHEST : X-

Ray

7. DATA ANALYSIS METHODS

7.1. Sample Size

A minimum of ********* patients will be recruited to commence the study in order to

detect the minimum relevant clinical difference at a statistical power of 80 % and p=0.05.

RCT Asthma 15
 Anti Asthma Drug

7.2. Randomization

Patients will be randomized 1:1

1 (Control group) : Standard Life Style

1 Treatment Group (Herbomineral Preparation)
fashion and followed for one year.

7.3. General Consideration

As this is a randomized controlled trial, the primary analysis will be an intend-to-treat

(ITT) analysis whereby all comparisons will be made on the basis of the treatment group
to which patients are initially randomized.

A secondary as-treated analysis will also be performed based solely on those patients
deemed to be evaluable throughout the study. This as-treated analysis will directly access
the effectiveness of treatment regimes with respect to the primary and secondary outcome
variables.

7.4. Statistical Methods

Student‘t’ test and repeated measure ANOVA.

8. DATA COLLECTION

8.1. Demographics

Demographic measure includes age, gender and race.

9. CLINICAL AND LAB PROCEDURES

9.1. Clinical Laboratory Assesments

RCT Asthma 16
 Anti Asthma Drug

10. REFERENCES

1. Zhao J, Takamura M, Yamaoka A, Odajima Y, Iikura Y. Altered eosinophil levels as a

result of viral infection in asthma exacerbation in childhood. J Pediatr Allergy Immunol.
2002 Feb;13(1):47–50. PMID 12000498

2. Lilly CM. Diversity of asthma: Evolving concepts of pathophysiology and lessons

from genetics. J Allergy Clin Immunol. 2005;115 (4 Suppl):S526-31. PMID 15806035

3. Marketos SG, Ballas CN. Bronchial asthma in the medical literature of Greek
antiquity. J Asthma. 1982;19(4):263-9. PMID 6757243

4. Rosner F. Moses Maimonides' treatise on asthma. Thorax. 1981;36:245–251. PMID

7025335

5. McFadden ER, Jr (2004). "Asthma", Harrison's Principles of Internal Medicine

(Kasper DL, Fauci AS, Longo DL, et al (eds)), 16th ed., New York: McGraw-Hill, 1508–
16. 

6. Longmore, Murray et al (2007). Oxford Handbook of Clinical Medicine, 7th ed.,

Oxford University Press. ISBN 978-0198568377. 

7. Pinnock H, Shah R (2007). "Asthma". Br Med J 334 (7598): 847–50.

DOI:10.1136/bmj.39140.634896.BE. 

8. Maddox L, Schwartz DA. The Pathophysiology of Asthma. Annu. Rev. Med. 2002,
53:477-98. PMID 11818486

9. Blanc PD, Trupin L, Earnest G, et al. Alternative therapies among adults with a
reported diagnosis of asthma or rhinosinusitis: data from a population-based survey.
Chest. 2001;120(5):1461–7. PMID 11713120

10. Shenfield G, Lim E, Allen H. Survey of the use of complementary medicines and
therapies in children with asthma. J Paediatr Child Health. 2002;38(3):252-7. PMID
12047692

11. McCarney RW, Brinkhaus B, Lasserson TJ, et al. Acupuncture for chronic asthma.
Cochrane Database Syst Rev. 2004;(1):CD000008. PMID 14973944

12. Blackhall K, Appleton S, Cates CJ. Ionisers for chronic asthma. Cochrane Database
Syst Rev. 2003;(3):CD002986 PMID 12917939

13. Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database
Syst Rev. 2005;(2):CD001002. PMID 15846609

RCT Asthma 17
 Anti Asthma Drug

14. Reilly D, Taylor MA, Beattie NG, et al. Is evidence for homoeopathy reproducible?
Lancet. 1994;344(8937):1601–6. PMID 7983994

15. White A, Slade P, Hunt C, et al. Individualised homeopathy as an adjunct in the

treatment of childhood asthma: a randomised placebo controlled trial. Thorax.
2003;58(4):317-21. PMID 12668794

16. Nagendra HR, Nagarathna R. An integrated approach of yoga therapy for bronchial
asthma: a 3-54-month prospective study. J Asthma. 1986;23(3):123-37. PMID 3745111

17. Manocha R, Marks GB, Kenchington P, et al. Sahaja yoga in the management of
moderate to severe asthma: a randomised controlled trial. Thorax. 2002;57(2):110-5.
PMID 11828038

18. Acharya Charak , Charak Samhita Part-II Chikitsa Sthana, Swas Rog Chikitsa

19. Szelenyi, I., Brune, K, Herbal remedies for asthma treatment: Between myth and
reality, Drugs Today 2002, 38(4): 265 ISSN 1699-3993.

20. 20. Jayant N. Dhuley, Antitussive effect of Adhatoda vasica extract on mechanical
or chemical stimulation-induced coughing in animals, Journal of Ethnopharmacology
Volume 67, Issue 3, 30 November 1999, Pages 361-365

21. Ubonwan Pongprayoon Claeson, Torbjörn Malmfors, Georg Wikman and Jan
G. Bruhn, Adhatoda vasica: a critical review of ethnopharmacological and toxicological
data, Journal of Ethnopharmacology Volume 72, Issues 1-2, 1 September 2000, Pages
1-20

22. Dorsch W, Wagner H., New antiasthmatic drugs from traditional medicine?, Int Arch
Allergy Appl Immunol. 1991;94(1-4):262-5.

23. Homma M, Oka K, Niitsuma T, Itoh H, A novel 11 beta-hydroxysteroid

dehydrogenase inhibitor contained in saiboku-to, a herbal remedy for steroid-dependent
bronchial asthma. J Pharm Pharmacol. 1994 Apr;46(4):305-9.

24. V. Vats, S. P. Yadav and J. K. Grover, Ethanolic extract of Ocimum sanctum leaves
partially attenuates streptozotocin-induced alterations in glycogen content and
carbohydrate metabolism in rats; Journal of Ethnopharmacology Volume 90, Issue 1,
January 2004, Pages 155-160

25. Sharma, GP, Sachitra Ayurveda, Apr., 665, 1983 as reported in Selected Med Plants
of India, Chemexcil, Bombay, 225-227, 1992.

26. Singh, TJ, Dasgupta, P, Khan, SY, and Mishra, KC, Preliminary pharmacological
investigations of Ocimum sanctum, Ind J Pharm., 32, 92, 1970.

RCT Asthma 18
 Anti Asthma Drug

27. Bhat, JV and Broker R, Action of some plant extracts on pathogenic staphlococci, J
Sci Ind Res Sect. B, 12, 540, 1953.

28. Isabella Schöll, Erika Jensen-Jarolim, Allergenic Potency of Spices: Hot, Medium
Hot, or Very Hot, International Archives of Allergy and Immunology 2004;135:247-261
(DOI: 10.1159/000081950)

29. Bordia A, Verma SK, Srivastava KC., Effect of ginger (Zingiber officinale Rosc.) and
fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet
aggregation in patients with coronary artery disease., Prostaglandins Leukot Essent Fatty
Acids. 1997 May;56(5):379-84, PMID: 9175175 [PubMed - indexed for MEDLINE]

30. P.M. Murali S. Rajasekaran O.R. Krishnarajasekar T. Perumal K. Nalini

S. Lakshmisubramanian C.N. Deivanayagam, Plant-Based Formulation for Bronchial
Asthma:A Controlled Clinical Trial to Compare Its Efficacy with Oral Salbutamol and
Theophylline, Respiration 2006;73:457–463

31. Lai P.K, Roy J, Antimicrobial and Chemopreventive Properties of Herbs and Spices,
Current Medicinal Chemistry, Volume 11, Number 11, June 2004 , pp. 1451-1460(10)

32. Datura stramonium From Wikipedia, the free encyclopedia, http://en.wikipedia.org

/wiki/Datura_stramonium
33. INDIAN AYURVEDIC & SIDDHA HERBS,
http://www.infomine.ae/all_herb.htm
34. http://www.indigoherbal.co.uk/man_index.htm
35. Chaturvedi, G.N., S.K. Tiwari and S.P. Sen (1976) - Experimental studies on
bharangi (Gardenia turgida), an indigenous drug used for the treatment of bronchial
asthma, JRIM 11, 4, 100-103.

36. Dahanukar, S.A., S.M. Karandikar and M. Desai (1984) - Efficacy of Piper longum in
childhood asthma, Indian Drugs 21, 9, 384-388.

37. Fernandes, A., F. Taraves and V.B. Athavale (1980) - Asthma in children: a clinical
controlled study of Piper longum in asthma, Paediatr. Clin. India 15, 4, 45.

38. Govindan, S., S. Viswanathan, V. Vijayasekaran and R. Alagappan (1999) - A pilot

study on the clinical efficacy of Solanum xanthocarpum and Solanum trilobatum in
bronchial asthma, Journal of Ethnopharmacology 66, 2, 205-210.

39. Govindan, S., S. Viswanathan, V. Vijayasekaran and R. Alagappan (2004) - Further

studies on the clinical efficacy of Solanum xanthocarpum and Solanum trilobatum in
bronchial asthma, Phytotherapy Research 18, 10, 805-809.

RCT Asthma 19
 Anti Asthma Drug

40. Goyal, H.R. (Ed.) (1997a) - Tamaka shwasa (bronchial asthma): a clinical study,
Central Council for Research in Ayurveda and Siddha, Ministry of Health and Family
Welfare, Government of India, New Delhi.

41. Goyal, H.R. and Keerti Sharma (1978) - Effect of swasa kesri tablet on tamak shwasa
- bronchial asthma (a clinical trial on 173 cases), Nagarjun 21, 4, 1-4.

42. Gupta, S.S. (1971) - Indigenous drugs in experimental bronchial asthma, Aspects
Allerg. Applied Immunol. 5, 31-42.

43. Gupta, S.S., Mahesh Rai and N.K. Gupta (1967a) - Histamine releasing effects of a
few Indian medicinal plants used in bronchial asthma, Current Science 36, 2, 42-43.

44. Gupta, S.S., S.C.L. Verma, C.M. Singh, (Mrs.) P. Khandelwal, N.K. Gupta and K.K.
Sapena (1967) - Chemical and pharmacological studies on Solanum xanthocarpum
(kantakari) in chronic bronchitis, bronchial asthma and non-specific unproductive cough,
IJMR 55, 7, 723-732.

45. Huntley, A. and E. Ernst (2000) - Herbal medicines for asthma: a systematic review,
Thorax 55, 925-929.

46. Kaid, A.A. and P.H. Kulkarni (1995) - Assessment of effect of swas kuttar, an
Ayurvedic product in case of bronchial asthma, Deerghayu International 11, 1, 17-20.
47. Kulkarni, P.H. (2001f) - Bronchial asthma care in Ayurveda and holistic systems, 155
p., Sri Satguru Publications, Delhi.
[ISBN 81-7030-713-9]

48. Mahadeva, K., H.I. Chandrasekara, D.H. Rajapaksa, K.D. Dharmasena, E.

Karunanayake, S. Weerakoon, J. Thilainathan, S. Arunachalam and S. Goonetilleke
(1969) - Evaluation of the effect of Ayurvedic drugs in the treatment of bronchial asthma,
Ayurveda Pradeepika.

49. Mardikar, B.R. (1999) - A clinical evaluation of an Ayurvedic expectorant in cases of

bronchial asthma, Antiseptic 96, 8, 303-307.

50. Miller, A.L. (2001) - The etiologies, pathophysiology, and alternative/complementary

treatment of asthma, Alternative Medicine Review 6, 1, 20-47.
[on Boswellia serrata Roxb. ex Colebr., quercetin, and Tylophora indica (Burm.f.) Mill. =
T. asthmatica (Linn.f.) Wight et Arn.

51. Mustaquem, M. (1994) - Household remedies for asthma, =Aryavaidyan 7, 3, 157-

161.

52. Pandya, M.M. (1981c) - Therapeutic value of Solanum xanthocarpum (kantkari) in

bronchial asthma, Sachitra Ayurved 33, 12, 729-733.

RCT Asthma 20
 Anti Asthma Drug

53. Saily, A., R. Sahu, B. Gupta and S.M. Sondhi (1994) - Analysis for mineral elements
of medicinal plants used for the treatment of asthma, syphilis, diarrhoea, skin diseases
and rheumatism, Hamdard Medicus 37, 4, 18-22.

54. Shankar, Ajai, M.R. Parsai, S.M.A. Naqvi and J.P. Jain (1980) - A clinical trial of
bharangi in cases of tamaka swasa (bronchial asthma), Journal of Research in Ayurveda
and Siddha 1, 4, 470-478.

55 Sharma, Keerti, Ajit S. Puri, H.R. Goyal and D.N. Sharma (1973) - Tamak shwasa
(bronchial asthma) - A clinical study, JRIM 8, 3, 8-13.

56. Sharma, Keerti, Ajit S. Puri and B.N. Sannd (1971) - Role of kantkari (Solanum
xanthocarpum) in shwas and kas - bronchial asthma and non-specific cough, JRIM 6, 2,
200-201.

57. Sharma, P.P. and J.M. Sharma (1992) - Therapeutic evaluation of Calotropis spp. in
management of bronchial asthma - a clinical study, International Seminar on Traditional
Medicine, Calcutta, 7-9th Dec., 1992, 86-87.

58. Singh, Gyan et al. (1985) - Herbal drugs for asthma - A review of clinical evaluation
of anti-asthmatic drugs, Indian Drugs 26, 11.

59. Singh, V.K. (1986) - Selected Indian folk claims for the cure of bronchial asthma,
JREIM 5, 3/4, 37-43; also in: Indian Journal of Applied and Pure Biology 1, 2, 92-97.

60. Upadhyay, S.D. and N.N. Pandey (1990) - Clinical evaluation of pippali (Piper
longum Linn.) kshirpaka in the treatment of bronchial asthma - a preliminary study,
=Aryavaidyan 11, 133-136; also in Nagarjun 25, 11, 1982, 250-258.

61. Paramesh H, Epidemiology of asthma in India., Year : 2002 Volume : 69 Issue : 4 

Page : 309-12

RCT Asthma 21